IL13RA2 and glioblastoma: Targeted knockdown of IL-13Rα2 in primary wtEGFR-positive GBM patient tumor, as validated by western blot analysis (Supplementary Fig. 7c), also did not affect cell proliferation (Supplementary Fig. 7d) nor cell migration (Supplementary Fig. 7e).